Anti-PD-L1 antibody treatment post-RFA sustained the inhibition of tumor growth through day 10, demonstrating the therapeutic potential of combining RFA with ICB to enhance anti-tumor immunity and prevent tumor relapse (Figure 3). This evidence concerns the gene CD274 and neoplasm.